<DOC>
	<DOC>NCT01210287</DOC>
	<brief_summary>The aim of this study is to identify the incidence of hepatitis B virus reactivation rate in Diffuse Large B Cell or high grade Follicular lymphoma patients with prior resolved hepatitis B undergoing RCHOP immuno-chemotherapy.</brief_summary>
	<brief_title>Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Naive DLBCL or high grade FL patients Age range 1875 years old ECOG performance status 03 Life expectancy of more than 3 months Adequate organ function HBsAg negative/HBcAb positive at baseline Infection of HAV,HCV,HIV Pregnant or lactating women Serious uncontrolled diseases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>hepatitis B virus reactivation</keyword>
	<keyword>HBsAg negative</keyword>
	<keyword>HBcAb positive</keyword>
	<keyword>lymphoma</keyword>
	<keyword>rituximab</keyword>
</DOC>